Reported 1 day ago
Madrigal Pharmaceuticals, Inc. (MDGL) has announced promising results from its Phase 3 trial of Rezdiffra (resmetirom), showing a 51% reduction in liver stiffness among participants with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis. At the EASL Congress 2025, data indicated significant improvements in liver health and a move to lower-risk categories for patients with portal hypertension. The company also received a positive opinion from the EMA for potential EU approval, positioning Rezdiffra to become the first approved MASH treatment in both the U.S. and Europe.
Source: YAHOO